Tekla Life Sciences Investors (NYSE: HQL) Stock Competitors & Peer Comparison
See HQL's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Asset Management Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HQL and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HQL | $21.55 | -3.71% | 656.2M | -51.88 | -$0.42 | +10.40% |
| VSMPX | $344.31 | +0.15% | 2.4T | 26.94 | $12.82 | N/A |
| VTSAX | $183.52 | +0.15% | 2.4T | 26.94 | $6.83 | +1.02% |
| VITSX | $183.55 | +0.15% | 2.3T | -1534.75 | -$0.12 | N/A |
| PMFLX | $9.99 | -0.10% | 1.9T | N/A | N/A | N/A |
| VFFSX | $374.96 | +0.16% | 1.7T | 27.46 | $13.69 | N/A |
| VFIAX | $707.16 | +0.16% | 1.7T | 27.46 | $25.82 | N/A |
| VFINX | $707.21 | +0.16% | 1.7T | 27.47 | $25.82 | N/A |
| VOO | $701.83 | -0.27% | 1.7T | 27.39 | $25.62 | +1.05% |
| FXAIX | $266.26 | +0.16% | 836.2B | N/A | N/A | N/A |
Stock Comparison
Vanguard Total Stock Market Index Fund Institutional Plus Shares (NASDAQ: VSMPX)
HQL vs VSMPX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VSMPX has a market cap of 2.4T. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VSMPX trades at $344.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VSMPX's P/E ratio is 26.94. In terms of profitability, HQL's ROE is +0.37%, compared to VSMPX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VSMPX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VSMPX's competition here
Vanguard Total Stock Market Index Fund Admiral Shares (NASDAQ: VTSAX)
HQL vs VTSAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VTSAX has a market cap of 2.4T. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VTSAX trades at $183.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VTSAX's P/E ratio is 26.94. In terms of profitability, HQL's ROE is +0.37%, compared to VTSAX's ROE of +0.08%. Regarding short-term risk, HQL is more volatile compared to VTSAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VTSAX's competition here
Vanguard Total Stock Market Index Fund Institutional Shares (NASDAQ: VITSX)
HQL vs VITSX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VITSX has a market cap of 2.3T. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VITSX trades at $183.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VITSX's P/E ratio is -1534.75. In terms of profitability, HQL's ROE is +0.37%, compared to VITSX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VITSX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VITSX's competition here
PIMCO Flexible Municipal Income Fund (NASDAQ: PMFLX)
HQL vs PMFLX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, PMFLX has a market cap of 1.9T. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while PMFLX trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas PMFLX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to PMFLX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to PMFLX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check PMFLX's competition here
Vanguard 500 Index Fund (NASDAQ: VFFSX)
HQL vs VFFSX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VFFSX has a market cap of 1.7T. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VFFSX trades at $374.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VFFSX's P/E ratio is 27.46. In terms of profitability, HQL's ROE is +0.37%, compared to VFFSX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VFFSX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VFFSX's competition here
Vanguard 500 Index Fund Admiral Shares (NASDAQ: VFIAX)
HQL vs VFIAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VFIAX has a market cap of 1.7T. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VFIAX trades at $707.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VFIAX's P/E ratio is 27.46. In terms of profitability, HQL's ROE is +0.37%, compared to VFIAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VFIAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VFIAX's competition here
Vanguard 500 Index Fund (NASDAQ: VFINX)
HQL vs VFINX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VFINX has a market cap of 1.7T. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VFINX trades at $707.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VFINX's P/E ratio is 27.47. In terms of profitability, HQL's ROE is +0.37%, compared to VFINX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VFINX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VFINX's competition here
Vanguard S&P 500 ETF (AMEX: VOO)
HQL vs VOO Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VOO has a market cap of 1.7T. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VOO trades at $701.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VOO's P/E ratio is 27.39. In terms of profitability, HQL's ROE is +0.37%, compared to VOO's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to VOO. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VOO's competition here
Fidelity 500 Index Fund (NASDAQ: FXAIX)
HQL vs FXAIX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FXAIX has a market cap of 836.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FXAIX trades at $266.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FXAIX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to FXAIX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FXAIX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FXAIX's competition here
State Street SPDR S&P 500 ETF (AMEX: SPY)
HQL vs SPY Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, SPY has a market cap of 813.4B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while SPY trades at $763.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas SPY's P/E ratio is 25.87. In terms of profitability, HQL's ROE is +0.37%, compared to SPY's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to SPY. This indicates higher risk in terms of short-term price fluctuations for HQL.Check SPY's competition here
Vanguard Total International Stock Index Fund Institutional Plus Shares (NASDAQ: VTPSX)
HQL vs VTPSX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VTPSX has a market cap of 673.3B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VTPSX trades at $187.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VTPSX's P/E ratio is 18.38. In terms of profitability, HQL's ROE is +0.37%, compared to VTPSX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VTPSX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VTPSX's competition here
Vanguard Total International Stock Index Fund Admiral Shares (NASDAQ: VTIAX)
HQL vs VTIAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VTIAX has a market cap of 673.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VTIAX trades at $46.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VTIAX's P/E ratio is 18.38. In terms of profitability, HQL's ROE is +0.37%, compared to VTIAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VTIAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VTIAX's competition here
Vanguard Total International Stock Index Fund Institutional Shares (NASDAQ: VTSNX)
HQL vs VTSNX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VTSNX has a market cap of 668.9B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VTSNX trades at $187.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VTSNX's P/E ratio is 18.38. In terms of profitability, HQL's ROE is +0.37%, compared to VTSNX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VTSNX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VTSNX's competition here
Invesco QQQ Trust, Series 1 (NASDAQ: QQQ)
HQL vs QQQ Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, QQQ has a market cap of 503.3B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while QQQ trades at $706.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas QQQ's P/E ratio is 32.43. In terms of profitability, HQL's ROE is +0.37%, compared to QQQ's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to QQQ. This indicates higher risk in terms of short-term price fluctuations for HQL.Check QQQ's competition here
BNY Mellon Municipal Opportunities ETF (NASDAQ: BMOP)
HQL vs BMOP Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, BMOP has a market cap of 434B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while BMOP trades at $24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas BMOP's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to BMOP's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to BMOP. This indicates higher risk in terms of short-term price fluctuations for HQL.Check BMOP's competition here
Vanguard Total Bond Market Index Fund (NASDAQ: VBMFX)
HQL vs VBMFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VBMFX has a market cap of 398.3B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VBMFX trades at $9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VBMFX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to VBMFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VBMFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VBMFX's competition here
Vanguard Growth Index Fund Admiral Shares (NASDAQ: VIGAX)
HQL vs VIGAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VIGAX has a market cap of 389.4B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VIGAX trades at $268.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VIGAX's P/E ratio is 33.77. In terms of profitability, HQL's ROE is +0.37%, compared to VIGAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VIGAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VIGAX's competition here
Vanguard Growth Index Fund Institutional Shares (NASDAQ: VIGIX)
HQL vs VIGIX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VIGIX has a market cap of 389.4B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VIGIX trades at $268.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VIGIX's P/E ratio is 33.77. In terms of profitability, HQL's ROE is +0.37%, compared to VIGIX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VIGIX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VIGIX's competition here
Vanguard Morningstar Growth ETF (AMEX: VUG)
HQL vs VUG Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VUG has a market cap of 387B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VUG trades at $86.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VUG's P/E ratio is 33.55. In terms of profitability, HQL's ROE is +0.37%, compared to VUG's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to VUG. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VUG's competition here
American Funds The Growth Fund of America® Class F-2 (NASDAQ: GFFFX)
HQL vs GFFFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, GFFFX has a market cap of 369.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while GFFFX trades at $87.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas GFFFX's P/E ratio is 32.64. In terms of profitability, HQL's ROE is +0.37%, compared to GFFFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to GFFFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check GFFFX's competition here
The Growth Fund of America Class F-1 Shares (NASDAQ: GFAFX)
HQL vs GFAFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, GFAFX has a market cap of 369.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while GFAFX trades at $86.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas GFAFX's P/E ratio is 33.42. In terms of profitability, HQL's ROE is +0.37%, compared to GFAFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to GFAFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check GFAFX's competition here
American Funds Growth Fund of Amer 529A (NASDAQ: CGFAX)
HQL vs CGFAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, CGFAX has a market cap of 369.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while CGFAX trades at $85.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas CGFAX's P/E ratio is 33.43. In terms of profitability, HQL's ROE is +0.37%, compared to CGFAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to CGFAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check CGFAX's competition here
Vanguard Institutional Index Fund Institutional Plus Shares (NASDAQ: VIIIX)
HQL vs VIIIX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VIIIX has a market cap of 358.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VIIIX trades at $613.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VIIIX's P/E ratio is 27.46. In terms of profitability, HQL's ROE is +0.37%, compared to VIIIX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VIIIX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VIIIX's competition here
Vanguard Institutional Index Fund Institutional Shares (NASDAQ: VINIX)
HQL vs VINIX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VINIX has a market cap of 358.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VINIX trades at $613.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VINIX's P/E ratio is 27.46. In terms of profitability, HQL's ROE is +0.37%, compared to VINIX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VINIX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VINIX's competition here
American Funds The Growth Fund of America Class R-6 (NASDAQ: RGAGX)
HQL vs RGAGX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RGAGX has a market cap of 356.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RGAGX trades at $87.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RGAGX's P/E ratio is 33.47. In terms of profitability, HQL's ROE is +0.37%, compared to RGAGX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RGAGX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RGAGX's competition here
American Funds The Growth Fund of America Class F-3 (NASDAQ: GAFFX)
HQL vs GAFFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, GAFFX has a market cap of 356.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while GAFFX trades at $87.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas GAFFX's P/E ratio is 33.47. In terms of profitability, HQL's ROE is +0.37%, compared to GAFFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to GAFFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check GAFFX's competition here
American Funds The Growth Fund of America Class A (NASDAQ: AGTHX)
HQL vs AGTHX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AGTHX has a market cap of 356.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AGTHX trades at $87.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AGTHX's P/E ratio is 33.43. In terms of profitability, HQL's ROE is +0.37%, compared to AGTHX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AGTHX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AGTHX's competition here
Vanguard Developed Markets Index Fund Admiral Shares (NASDAQ: VTMGX)
HQL vs VTMGX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VTMGX has a market cap of 328.1B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VTMGX trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VTMGX's P/E ratio is 18.94. In terms of profitability, HQL's ROE is +0.37%, compared to VTMGX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VTMGX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VTMGX's competition here
Vanguard Developed Markets Index Fund Institutional Plus Shares (NASDAQ: VDIPX)
HQL vs VDIPX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VDIPX has a market cap of 328.1B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VDIPX trades at $36.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VDIPX's P/E ratio is 18.94. In terms of profitability, HQL's ROE is +0.37%, compared to VDIPX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VDIPX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VDIPX's competition here
Vanguard Developed Markets Index Fund Institutional Shares (NASDAQ: VTMNX)
HQL vs VTMNX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VTMNX has a market cap of 326.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VTMNX trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VTMNX's P/E ratio is 18.94. In terms of profitability, HQL's ROE is +0.37%, compared to VTMNX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VTMNX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VTMNX's competition here
Vanguard FTSE Developed Markets ETF (AMEX: VEA)
HQL vs VEA Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VEA has a market cap of 326.4B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VEA trades at $73.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VEA's P/E ratio is 18.84. In terms of profitability, HQL's ROE is +0.37%, compared to VEA's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to VEA. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VEA's competition here
American Funds American Balanced Fund (NASDAQ: AFMBX)
HQL vs AFMBX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AFMBX has a market cap of 292.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AFMBX trades at $41.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AFMBX's P/E ratio is 26.71. In terms of profitability, HQL's ROE is +0.37%, compared to AFMBX's ROE of +0.13%. Regarding short-term risk, HQL is more volatile compared to AFMBX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AFMBX's competition here
American Funds American Balanced F1 (NASDAQ: BALFX)
HQL vs BALFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, BALFX has a market cap of 292.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while BALFX trades at $40.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas BALFX's P/E ratio is 26.69. In terms of profitability, HQL's ROE is +0.37%, compared to BALFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to BALFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check BALFX's competition here
American Funds American Balanced A (NASDAQ: ABALX)
HQL vs ABALX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, ABALX has a market cap of 292.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while ABALX trades at $41.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas ABALX's P/E ratio is 26.69. In terms of profitability, HQL's ROE is +0.37%, compared to ABALX's ROE of +0.13%. Regarding short-term risk, HQL is more volatile compared to ABALX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check ABALX's competition here
American Funds American Balanced Fund Class R-6 (NASDAQ: RLBGX)
HQL vs RLBGX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RLBGX has a market cap of 287.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RLBGX trades at $41.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RLBGX's P/E ratio is 26.70. In terms of profitability, HQL's ROE is +0.37%, compared to RLBGX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RLBGX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RLBGX's competition here
American Balanced Fund Class F-2 Shs (NASDAQ: AMBFX)
HQL vs AMBFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AMBFX has a market cap of 287.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AMBFX trades at $40.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AMBFX's P/E ratio is 26.70. In terms of profitability, HQL's ROE is +0.37%, compared to AMBFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AMBFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AMBFX's competition here
American Funds American Balanced 529A (NASDAQ: CLBAX)
HQL vs CLBAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, CLBAX has a market cap of 287.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while CLBAX trades at $40.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas CLBAX's P/E ratio is 26.69. In terms of profitability, HQL's ROE is +0.37%, compared to CLBAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to CLBAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check CLBAX's competition here
American Funds The Growth Fund of America Class R-2 (NASDAQ: RGABX)
HQL vs RGABX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RGABX has a market cap of 271.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RGABX trades at $76.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RGABX's P/E ratio is 32.44. In terms of profitability, HQL's ROE is +0.37%, compared to RGABX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RGABX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RGABX's competition here
The Growth Fund of America Class R-1 Shares (NASDAQ: RGAAX)
HQL vs RGAAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RGAAX has a market cap of 266.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RGAAX trades at $74.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RGAAX's P/E ratio is 32.44. In terms of profitability, HQL's ROE is +0.37%, compared to RGAAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RGAAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RGAAX's competition here
Strategic Advisers Fidelity US TtlStk (NASDAQ: FCTDX)
HQL vs FCTDX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FCTDX has a market cap of 264.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FCTDX trades at $22.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FCTDX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to FCTDX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FCTDX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FCTDX's competition here
Vanguard Morningstar Value ETF (AMEX: VTV)
HQL vs VTV Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VTV has a market cap of 262.1B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VTV trades at $226.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VTV's P/E ratio is 22.42. In terms of profitability, HQL's ROE is +0.37%, compared to VTV's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to VTV. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VTV's competition here
Vanguard Value Index Fund Admiral Shares (NASDAQ: VVIAX)
HQL vs VVIAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VVIAX has a market cap of 261.9B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VVIAX trades at $88.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VVIAX's P/E ratio is 22.39. In terms of profitability, HQL's ROE is +0.37%, compared to VVIAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VVIAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VVIAX's competition here
American Funds The Growth Fund of America (NASDAQ: GFACX)
HQL vs GFACX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, GFACX has a market cap of 259.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while GFACX trades at $72.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas GFACX's P/E ratio is 33.33. In terms of profitability, HQL's ROE is +0.37%, compared to GFACX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to GFACX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check GFACX's competition here
Schwab Value Advantage Money Fund (NASDAQ: SWVXX)
HQL vs SWVXX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, SWVXX has a market cap of 245.3B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while SWVXX trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas SWVXX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to SWVXX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to SWVXX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check SWVXX's competition here
PIMCO Income Fund (NASDAQ: PIMIX)
HQL vs PIMIX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, PIMIX has a market cap of 231.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while PIMIX trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas PIMIX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to PIMIX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to PIMIX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check PIMIX's competition here
PIMCO Income Fund (NASDAQ: PONPX)
HQL vs PONPX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, PONPX has a market cap of 231.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while PONPX trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas PONPX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to PONPX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to PONPX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check PONPX's competition here
Vanguard Mid-Cap Index Fund Institutional Plus Shares (NASDAQ: VMCPX)
HQL vs VMCPX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VMCPX has a market cap of 229.7B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VMCPX trades at $446.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VMCPX's P/E ratio is 24.57. In terms of profitability, HQL's ROE is +0.37%, compared to VMCPX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VMCPX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VMCPX's competition here
Vanguard Mid-Cap Index Fund Admiral Shares (NASDAQ: VIMAX)
HQL vs VIMAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VIMAX has a market cap of 229.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VIMAX trades at $410.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VIMAX's P/E ratio is 24.57. In terms of profitability, HQL's ROE is +0.37%, compared to VIMAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VIMAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VIMAX's competition here
Vanguard Mid-Cap Index Fund Institutional Shares (NASDAQ: VMCIX)
HQL vs VMCIX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VMCIX has a market cap of 229.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VMCIX trades at $90.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VMCIX's P/E ratio is 24.57. In terms of profitability, HQL's ROE is +0.37%, compared to VMCIX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VMCIX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VMCIX's competition here
Vanguard Morningstar Mid-Cap ETF (AMEX: VO)
HQL vs VO Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VO has a market cap of 229.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VO trades at $82.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VO's P/E ratio is 24.52. In terms of profitability, HQL's ROE is +0.37%, compared to VO's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to VO. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VO's competition here
Oaktree Diversified Income Fund Inc. (NASDAQ: ODIDX)
HQL vs ODIDX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, ODIDX has a market cap of 213.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while ODIDX trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas ODIDX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to ODIDX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to ODIDX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check ODIDX's competition here
Vanguard Small-Cap Index Fund Admiral Shares (NASDAQ: VSMAX)
HQL vs VSMAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VSMAX has a market cap of 194.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VSMAX trades at $145.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VSMAX's P/E ratio is 22.29. In terms of profitability, HQL's ROE is +0.37%, compared to VSMAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VSMAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VSMAX's competition here
Vanguard Small-Cap Index Fund Institutional Shares (NASDAQ: VSCIX)
HQL vs VSCIX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VSCIX has a market cap of 194.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VSCIX trades at $145.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VSCIX's P/E ratio is 22.29. In terms of profitability, HQL's ROE is +0.37%, compared to VSCIX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VSCIX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VSCIX's competition here
Vanguard Morningstar Small-Cap ETF (AMEX: VB)
HQL vs VB Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VB has a market cap of 193.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VB trades at $302.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VB's P/E ratio is 22.14. In terms of profitability, HQL's ROE is +0.37%, compared to VB's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to VB. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VB's competition here
Apollo Global Management, Inc. (NYSE: APO-PA)
HQL vs APO-PA Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, APO-PA has a market cap of 190.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while APO-PA trades at $170.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas APO-PA's P/E ratio is 20.43. In terms of profitability, HQL's ROE is +0.37%, compared to APO-PA's ROE of +0.09%. Regarding short-term risk, HQL is more volatile compared to APO-PA. This indicates higher risk in terms of short-term price fluctuations for HQL.Check APO-PA's competition here
American Funds Invmt Co of Amer R2 (NASDAQ: RICBX)
HQL vs RICBX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RICBX has a market cap of 186.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RICBX trades at $68.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RICBX's P/E ratio is 28.76. In terms of profitability, HQL's ROE is +0.37%, compared to RICBX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RICBX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RICBX's competition here
American Funds Investment Co of America C (NASDAQ: AICCX)
HQL vs AICCX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AICCX has a market cap of 186.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AICCX trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AICCX's P/E ratio is 28.76. In terms of profitability, HQL's ROE is +0.37%, compared to AICCX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AICCX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AICCX's competition here
Fidelity Contrafund K (NASDAQ: FCNKX)
HQL vs FCNKX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FCNKX has a market cap of 186B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FCNKX trades at $26.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FCNKX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to FCNKX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FCNKX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FCNKX's competition here
Fidelity Contrafund (NASDAQ: FCNTX)
HQL vs FCNTX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FCNTX has a market cap of 185.9B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FCNTX trades at $26.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FCNTX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to FCNTX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FCNTX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FCNTX's competition here
American Funds Fundamental Invs F2 (NASDAQ: FINFX)
HQL vs FINFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FINFX has a market cap of 183.9B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FINFX trades at $103.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FINFX's P/E ratio is 29.05. In terms of profitability, HQL's ROE is +0.37%, compared to FINFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FINFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FINFX's competition here
American Funds Fundamental Invs F3 (NASDAQ: FUNFX)
HQL vs FUNFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FUNFX has a market cap of 183.9B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FUNFX trades at $103.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FUNFX's P/E ratio is 29.06. In terms of profitability, HQL's ROE is +0.37%, compared to FUNFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FUNFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FUNFX's competition here
American Funds Fundamental Investors (NASDAQ: ANCFX)
HQL vs ANCFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, ANCFX has a market cap of 183.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while ANCFX trades at $103.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas ANCFX's P/E ratio is 29.05. In terms of profitability, HQL's ROE is +0.37%, compared to ANCFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to ANCFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check ANCFX's competition here
BlackRock, Inc. (NYSE: BLK)
HQL vs BLK Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, BLK has a market cap of 181.7B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while BLK trades at $1,172.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas BLK's P/E ratio is 22.92. In terms of profitability, HQL's ROE is +0.37%, compared to BLK's ROE of +0.12%. Regarding short-term risk, HQL is more volatile compared to BLK. This indicates higher risk in terms of short-term price fluctuations for HQL.Check BLK's competition here
American Funds Invmt Co of Amer F3 (NASDAQ: FFICX)
HQL vs FFICX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FFICX has a market cap of 181B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FFICX trades at $68.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FFICX's P/E ratio is 28.81. In terms of profitability, HQL's ROE is +0.37%, compared to FFICX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FFICX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FFICX's competition here
American Funds Investment Co of America Cl F-1 Shs (NASDAQ: AICFX)
HQL vs AICFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AICFX has a market cap of 181B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AICFX trades at $68.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AICFX's P/E ratio is 28.80. In terms of profitability, HQL's ROE is +0.37%, compared to AICFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AICFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AICFX's competition here
American Funds Invmt Co of Amer 529A (NASDAQ: CICAX)
HQL vs CICAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, CICAX has a market cap of 181B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while CICAX trades at $68.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas CICAX's P/E ratio is 28.80. In terms of profitability, HQL's ROE is +0.37%, compared to CICAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to CICAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check CICAX's competition here
American Funds Invmt Co of Amer A (NASDAQ: AIVSX)
HQL vs AIVSX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AIVSX has a market cap of 181B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AIVSX trades at $69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AIVSX's P/E ratio is 28.80. In terms of profitability, HQL's ROE is +0.37%, compared to AIVSX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AIVSX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AIVSX's competition here
American Funds Investment Company of America;R1 (NASDAQ: RICAX)
HQL vs RICAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RICAX has a market cap of 180.9B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RICAX trades at $68.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RICAX's P/E ratio is 28.76. In terms of profitability, HQL's ROE is +0.37%, compared to RICAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RICAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RICAX's competition here
American Funds Fundamental Investors Class F-1 (NASDAQ: AFIFX)
HQL vs AFIFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AFIFX has a market cap of 179.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AFIFX trades at $103.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AFIFX's P/E ratio is 29.05. In terms of profitability, HQL's ROE is +0.37%, compared to AFIFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AFIFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AFIFX's competition here
American Funds Fundamental Investors Class 529-A (NASDAQ: CFNAX)
HQL vs CFNAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, CFNAX has a market cap of 179.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while CFNAX trades at $103.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas CFNAX's P/E ratio is 29.04. In terms of profitability, HQL's ROE is +0.37%, compared to CFNAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to CFNAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check CFNAX's competition here
American Funds Fundamental Invs R3 (NASDAQ: RFNCX)
HQL vs RFNCX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RFNCX has a market cap of 179.1B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RFNCX trades at $102.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RFNCX's P/E ratio is 29.03. In terms of profitability, HQL's ROE is +0.37%, compared to RFNCX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RFNCX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RFNCX's competition here
New Perspective Fund - Class F-3 (NASDAQ: FNPFX)
HQL vs FNPFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FNPFX has a market cap of 175.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FNPFX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FNPFX's P/E ratio is 27.60. In terms of profitability, HQL's ROE is +0.37%, compared to FNPFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FNPFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FNPFX's competition here
New Perspective Fund, Class F-1 Shares (NASDAQ: NPFFX)
HQL vs NPFFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, NPFFX has a market cap of 175.4B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while NPFFX trades at $75.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas NPFFX's P/E ratio is 27.56. In terms of profitability, HQL's ROE is +0.37%, compared to NPFFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to NPFFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check NPFFX's competition here
Blackstone Inc. (NYSE: BX)
HQL vs BX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, BX has a market cap of 173.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while BX trades at $143.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas BX's P/E ratio is 24.59. In terms of profitability, HQL's ROE is +0.37%, compared to BX's ROE of +0.41%. Regarding short-term risk, HQL is more volatile compared to BX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check BX's competition here
American Funds New Perspective Fund Class R-6 (NASDAQ: RNPGX)
HQL vs RNPGX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RNPGX has a market cap of 171.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RNPGX trades at $76.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RNPGX's P/E ratio is 27.60. In terms of profitability, HQL's ROE is +0.37%, compared to RNPGX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RNPGX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RNPGX's competition here
American Funds New Perspective Fund Class A (NASDAQ: ANWPX)
HQL vs ANWPX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, ANWPX has a market cap of 171.6B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while ANWPX trades at $75.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas ANWPX's P/E ratio is 27.57. In terms of profitability, HQL's ROE is +0.37%, compared to ANWPX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to ANWPX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check ANWPX's competition here
American Funds New Perspective R3 (NASDAQ: RNPCX)
HQL vs RNPCX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RNPCX has a market cap of 171.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RNPCX trades at $73.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RNPCX's P/E ratio is 27.53. In terms of profitability, HQL's ROE is +0.37%, compared to RNPCX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RNPCX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RNPCX's competition here
Vanguard Emerging Markets Stock Index Fund Institutional Plus Shares (NASDAQ: VEMRX)
HQL vs VEMRX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VEMRX has a market cap of 168.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VEMRX trades at $125.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VEMRX's P/E ratio is 17.01. In terms of profitability, HQL's ROE is +0.37%, compared to VEMRX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VEMRX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VEMRX's competition here
SPAC and New Issue ETF (NASDAQ: SPCK)
HQL vs SPCK Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, SPCK has a market cap of 166.7B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while SPCK trades at $22.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas SPCK's P/E ratio is -20.00. In terms of profitability, HQL's ROE is +0.37%, compared to SPCK's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to SPCK. This indicates higher risk in terms of short-term price fluctuations for HQL.Check SPCK's competition here
Vanguard Emerging Markets Stock Index Fund Admiral Shares (NASDAQ: VEMAX)
HQL vs VEMAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, VEMAX has a market cap of 166.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while VEMAX trades at $49.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas VEMAX's P/E ratio is 17.01. In terms of profitability, HQL's ROE is +0.37%, compared to VEMAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to VEMAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check VEMAX's competition here
American Funds Capital World Gr&Inc F2 (NASDAQ: WGIFX)
HQL vs WGIFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, WGIFX has a market cap of 158.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while WGIFX trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas WGIFX's P/E ratio is 25.65. In terms of profitability, HQL's ROE is +0.37%, compared to WGIFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to WGIFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check WGIFX's competition here
American Funds Washington Mutual A (NASDAQ: AWSHX)
HQL vs AWSHX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AWSHX has a market cap of 155B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AWSHX trades at $69.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AWSHX's P/E ratio is 26.72. In terms of profitability, HQL's ROE is +0.37%, compared to AWSHX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AWSHX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AWSHX's competition here
American Funds Washington Mutual R5 (NASDAQ: RWMFX)
HQL vs RWMFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RWMFX has a market cap of 154.9B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RWMFX trades at $69.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RWMFX's P/E ratio is 26.73. In terms of profitability, HQL's ROE is +0.37%, compared to RWMFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RWMFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RWMFX's competition here
American Funds Washington Mutual F3 (NASDAQ: FWMIX)
HQL vs FWMIX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FWMIX has a market cap of 154.9B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FWMIX trades at $69.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FWMIX's P/E ratio is 26.73. In terms of profitability, HQL's ROE is +0.37%, compared to FWMIX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FWMIX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FWMIX's competition here
American Funds Washington Mutual 529A (NASDAQ: CWMAX)
HQL vs CWMAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, CWMAX has a market cap of 154.3B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while CWMAX trades at $68.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas CWMAX's P/E ratio is 26.72. In terms of profitability, HQL's ROE is +0.37%, compared to CWMAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to CWMAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check CWMAX's competition here
First Eagle Core Plus Municipal Fund Class A (NASDAQ: FPMAX)
HQL vs FPMAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FPMAX has a market cap of 154.1B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FPMAX trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FPMAX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to FPMAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FPMAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FPMAX's competition here
American Funds Washington Mutual F1 (NASDAQ: WSHFX)
HQL vs WSHFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, WSHFX has a market cap of 153.9B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while WSHFX trades at $68.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas WSHFX's P/E ratio is 26.71. In terms of profitability, HQL's ROE is +0.37%, compared to WSHFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to WSHFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check WSHFX's competition here
American Funds Washington Mutual C (NASDAQ: WSHCX)
HQL vs WSHCX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, WSHCX has a market cap of 151.4B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while WSHCX trades at $67.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas WSHCX's P/E ratio is 26.67. In terms of profitability, HQL's ROE is +0.37%, compared to WSHCX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to WSHCX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check WSHCX's competition here
American Funds Washington Mutual R2 (NASDAQ: RWMBX)
HQL vs RWMBX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RWMBX has a market cap of 150.8B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RWMBX trades at $67.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RWMBX's P/E ratio is 26.66. In terms of profitability, HQL's ROE is +0.37%, compared to RWMBX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RWMBX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RWMBX's competition here
SPDR Gold Shares (AMEX: GLD)
HQL vs GLD Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, GLD has a market cap of 150.5B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while GLD trades at $426.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas GLD's P/E ratio is 234456.04. In terms of profitability, HQL's ROE is +0.37%, compared to GLD's ROE of +0.00%. Regarding short-term risk, HQL is more volatile compared to GLD. This indicates higher risk in terms of short-term price fluctuations for HQL.Check GLD's competition here
Schwab S&P 500 Index Fund- Select Shares (NASDAQ: SWPPX)
HQL vs SWPPX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, SWPPX has a market cap of 147.7B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while SWPPX trades at $19.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas SWPPX's P/E ratio is 27.50. In terms of profitability, HQL's ROE is +0.37%, compared to SWPPX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to SWPPX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check SWPPX's competition here
American Funds Income Fund of Amer F3 (NASDAQ: FIFAX)
HQL vs FIFAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FIFAX has a market cap of 147.4B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FIFAX trades at $28.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FIFAX's P/E ratio is 20.09. In terms of profitability, HQL's ROE is +0.37%, compared to FIFAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FIFAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FIFAX's competition here
American Funds EUPAC R6 (NASDAQ: RERGX)
HQL vs RERGX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RERGX has a market cap of 146.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RERGX trades at $65.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RERGX's P/E ratio is 19.95. In terms of profitability, HQL's ROE is +0.37%, compared to RERGX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RERGX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RERGX's competition here
American Funds EuroPacific Growth Cl F-1 Shs (NASDAQ: AEGFX)
HQL vs AEGFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AEGFX has a market cap of 146.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AEGFX trades at $64.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AEGFX's P/E ratio is 19.91. In terms of profitability, HQL's ROE is +0.37%, compared to AEGFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AEGFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AEGFX's competition here
American Funds Europacific Growth R5E (NASDAQ: RERHX)
HQL vs RERHX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, RERHX has a market cap of 144.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while RERHX trades at $64.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas RERHX's P/E ratio is 19.92. In terms of profitability, HQL's ROE is +0.37%, compared to RERHX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to RERHX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check RERHX's competition here
American Funds EuroPacific Growth Fund (NASDAQ: AEPFX)
HQL vs AEPFX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AEPFX has a market cap of 144.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AEPFX trades at $64.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AEPFX's P/E ratio is 19.94. In terms of profitability, HQL's ROE is +0.37%, compared to AEPFX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AEPFX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AEPFX's competition here
American Funds EuroPacific Growth Fund Class A (NASDAQ: AEPGX)
HQL vs AEPGX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, AEPGX has a market cap of 144.2B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while AEPGX trades at $64.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas AEPGX's P/E ratio is 19.92. In terms of profitability, HQL's ROE is +0.37%, compared to AEPGX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to AEPGX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check AEPGX's competition here
Vanguard Small Cap Index Fund (NASDAQ: NAESX)
HQL vs NAESX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, NAESX has a market cap of 140.7B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while NAESX trades at $145.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas NAESX's P/E ratio is 22.29. In terms of profitability, HQL's ROE is +0.37%, compared to NAESX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to NAESX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check NAESX's competition here
Fidelity Total Market Index Fund (NASDAQ: FSKAX)
HQL vs FSKAX Comparison August 2026
Tekla Life Sciences Investors (NYSE: HQL) plays a significant role within the Financial Services sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HQL stands at 656.2M. In comparison, FSKAX has a market cap of 140B. Regarding current trading prices, HQL is priced at $21.55 on the NYSE, while FSKAX trades at $211.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HQL currently has a P/E ratio of -51.88, whereas FSKAX's P/E ratio is N/A. In terms of profitability, HQL's ROE is +0.37%, compared to FSKAX's ROE of N/A. Regarding short-term risk, HQL is more volatile compared to FSKAX. This indicates higher risk in terms of short-term price fluctuations for HQL.Check FSKAX's competition here